The process of discovery and development of a molecule is complex, long and costly. Before making a decision on the offer that best meets your needs, we offer online scientific resources and our latest news to help you get to know us better. Our experts are also at your disposal to help and support you in your research and development program.

Filter by BU or service
  • All
  • Corporate
  • Service
  • Biotech
  • A.I
  • Homing program
  • Financial
  • HR
Filter by BU or service
Filter by category
  • All
  • Webinar
  • Posters
  • Scientific publications
  • Press release
  • Press coverage
  • Media kit
  • News
Filter by category
loader

Scientific resources

Scientific publications

Service
04/09/2021

Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2

SARS-CoV-2; interferon-alpha; nafamostat; antiviral drug combination; broad-spectrum antivirals

Service
04/09/2021

Nafamostat-Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2

SARS-CoV-2; antiviral drug combination; broad-spectrum antivirals; interferon-alpha; nafamostat.

Biotech
12/06/2021

Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors

Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors

Service
19/05/2021

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models

Service
01/04/2021

Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models

Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models

Biotech
24/10/2014

In vivo inhibition of RIPK2 kinase alleviates inflammatory disease

In vivo inhibition of RIPK2 kinase alleviates inflammatory disease

Press

Press release

Karine Lignel | Senior Executive Vice President - Group Chief Development Officer - Oncodesign
Corporate
Financial
25/10/2021

Oncodesign has appointed Karine Lignel as Group Chief Development Officer

Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.

Karine Lignel | Senior Executive Vice President - Group Chief Development Officer - Oncodesign
Corporate
Financial
25/10/2021

Oncodesign has appointed Karine Lignel as Group Chief Development Officer

Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.

Oncodesign x TiumBio signed a collaboration agreement | Fibrosis
Biotech
21/10/2021

Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates

Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.

Financial
16/09/2021

Oncodesign announces its results for the first half of 2021

Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence.

Financial
21/07/2021

Oncodesign announces a sharp increase in turnover in the first half of 2021

Group turnover up by 33% at €15.8M. Despite the global health crisis, which continues to limit international travel...

Corporate
Financial
05/07/2021

Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors

Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.

Corporate
Financial
05/07/2021

Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors

Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.

SOLO-Pharmaco-Imaging
Service
01/07/2021

Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT

Discover the alliance of experts in radiopharmaceuticals: an innovative offer in therapeutic development in nuclear medicine from the validation of therapeutic targets, the generation of radiolabeled biological vectors, the optimization of leads, the generation of drug candidates to IND, the design and management of clinical trials.

SOLO-Pharmaco-Imaging
Service
Financial
28/06/2021

Oncodesign launches its new DRIVE-MRT™ service offer in partnership with Covalab, CheMatech and ABX-CRO

[Press Release] Explore our brand new service offer DRIVE-MRT. it allows the rationalization, design and optimization of targeted radiopharmaceutical products that are effective against certain metastatic cancers.

Biotech
Financial
24/06/2021

Oncodesign provides an update on its progress on RIPK2

[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.

Corporate
Service
07/11/2018

Service partnership agreement between Oncodesign and Galderma

Press Release: Multi-year service contract: design and discover new drug candidates in dermatology - Galderma.

Corporate
Service
07/11/2018

Service partnership agreement between Oncodesign and Galderma

Press Release: Multi-year service contract: design and discover new drug candidates in dermatology - Galderma.

Corporate
Service
15/10/2018

Centre Georges François Leclerc Presents the Detailed Results of the First Two Stages of its Clinical Study in Lung Cancer at the EANM Congress

Presentation of detailed results from the first two stages of the clinical trial in lung cancer | 31st EANM1 | 2018.

Corporate
Service
15/10/2018

Centre Georges François Leclerc Presents the Detailed Results of the First Two Stages of its Clinical Study in Lung Cancer at the EANM Congress

Presentation of detailed results from the first two stages of the clinical trial in lung cancer | 31st EANM1 | 2018.

Corporate
A.I
18/09/2018

Precision medicine: Cap Digital and Medicen Paris-Region team-up with Oncodesign, Servier and Intersystems on Hu-PreciMED

Hu-PreciMED project will gear French precision medicine industry towards discovering new diagnostic approaches & novel therapeutic treatments.

Press coverage

Media kit

Corporate

MEDIA KIT

Find all the media information of Oncodesign, logo, boiler plate, photos, press contacts

News

Karine Lignel | Senior Executive Vice President - Group Chief Development Officer - Oncodesign
Corporate
Financial
25/10/2021

Oncodesign has appointed Karine Lignel as Group Chief Development Officer

Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.

Oncodesign x TiumBio signed a collaboration agreement | Fibrosis
Biotech
21/10/2021

Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates

Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.

20/10/2021

[WEBINARS] Pharmaco-imaging, COVID-19, Microbiome…

[Webinars] Radiopharmaceutics, COVID-19, Microbiome… join us this fall during a webinar

Service
19/10/2021

[CONGRESS] Discovery UK: 26 – 27 October 2021

Oncodesign will be at the in-person event by Oxford Global in London, Discovery UK.

Financial
16/09/2021

Oncodesign announces its results for the first half of 2021

Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence.

Corporate
Financial
05/07/2021

Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors

Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.

Corporate
02/07/2021

Find out how we built our logo!

Oncodesign Find out how we built our logo! trajectory DNA innovation...green and bleue pharma colors Find out how we built our logo!

Corporate
01/07/2021

Brand new logo for Oncodesign

Brand new logo for Oncodesign. New graphic identity with evolutive look & feel approach... First element of our new logo.

Biotech
Financial
24/06/2021

Oncodesign provides an update on its progress on RIPK2

[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.

ressources-oncodesign
Service
23/06/2021

[Congress] Microbiome movement Drug Development Summit June 29 – July 1, 2021

Listen to our expert talk about “preclinical solutions for microbiome investigation in pathological situation and drug development”

Service
07/10/2019

[EN] [Congress] Start.Smart.Global 2019 – 7-10 October 2019: Roadshow in Japan & November 2019: Roadshow in South Korea

RoadShow in Japan and South Korean to demonstrate the potency and specificity of our innovative technology module Nanocyclix®

Corporate

Our brand Oncodesign

Our brand Oncodesign . Combination of the words oncology and design... Precision Medicine for patient... Oncodesign

There are no resources available for your request. Contact us directly via our contact form for any information request